BG
AKRO

Bellevue Group’s Akero Therapeutics AKRO Stock Holding History

Bellevue Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,389,314
Closed -$113M – 178
2025
Q3 		$113M Buy
2,389,314
+404,042
+20% +$19.6M 2.36% 14
2025
Q2 		$106M Buy
1,985,272
+734,606
+59% +$33.4M 2.33% 13
2025
Q1 		$50.6M Buy
+1,250,666
New +$53M 1.13% 22
2023
Q4 		– Sell
-25,000
Closed -$1.26M – 162
2023
Q3 		$1.26M Sell
25,000
-2,100
-8% -$97.8K 0.02% 121
2023
Q2 		$1.27M Buy
27,100
+1,000
+4% +$45.8K 0.02% 123
2023
Q1 		$999K Sell
26,100
-16,550
-39% -$738K 0.01% 129
2022
Q4 		$2.34M Buy
42,650
+1,016
+2% +$43.5K 0.03% 123
2022
Q3 		$1.42M Buy
+41,634
New +$637K 0.02% 129

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bellevue Group's AKRO Position: Q4 2025 in Review

Bellevue Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 2,389,314 shares — an estimated $113M sold.

Bellevue Group first reported a position in AKRO in Q3 2022 and held it in 8 quarters. The position peaked at $113M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Bellevue Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bellevue Group sold 2,389,314 Akero Therapeutics shares in Q4 2025, an estimated $113M.
  • Bellevue Group first reported a position in Akero Therapeutics in Q3 2022 and held it in 8 quarters.
  • Bellevue Group's Akero Therapeutics position peaked at $113M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.